- Home
- MASS vs MRSN Comparison
MASS vs MRSN Comparison
Compare MASS & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASS
- MRSN
- Stock Information
- Founded
- MASS 2012
- MRSN 2001
- Country
- MASS United States
- MRSN United States
- Employees
- MASS N/A
- MRSN N/A
- Industry
- MASS Medical/Dental Instruments
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- MASS Health Care
- MRSN Health Care
- Exchange
- MASS Nasdaq
- MRSN Nasdaq
- Market Cap
- MASS 84.3M
- MRSN 71.9M
- IPO Year
- MASS 2020
- MRSN 2017
- Fundamental
- Price
- MASS $2.53
- MRSN $0.53
- Analyst Decision
- MASS Buy
- MRSN Buy
- Analyst Count
- MASS 3
- MRSN 7
- Target Price
- MASS $5.33
- MRSN $6.00
- AVG Volume (30 Days)
- MASS 298.0K
- MRSN 5.4M
- Earning Date
- MASS 03-04-2025
- MRSN 03-07-2025
- Dividend Yield
- MASS N/A
- MRSN N/A
- EPS Growth
- MASS N/A
- MRSN N/A
- EPS
- MASS N/A
- MRSN N/A
- Revenue
- MASS $55,162,000.00
- MRSN $34,837,000.00
- Revenue This Year
- MASS $15.31
- MRSN N/A
- Revenue Next Year
- MASS $16.10
- MRSN N/A
- P/E Ratio
- MASS N/A
- MRSN N/A
- Revenue Growth
- MASS 16.08
- MRSN N/A
- 52 Week Low
- MASS $1.81
- MRSN $0.49
- 52 Week High
- MASS $7.91
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- MASS 49.72
- MRSN 32.86
- Support Level
- MASS $2.29
- MRSN $0.56
- Resistance Level
- MASS $3.05
- MRSN $0.82
- Average True Range (ATR)
- MASS 0.25
- MRSN 0.07
- MACD
- MASS 0.01
- MRSN 0.03
- Stochastic Oscillator
- MASS 33.33
- MRSN 8.39
About MASS 908 Devices Inc.
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.